A Phase I/II, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination with Bempegaldesleukin NKTR-214 and in Combination with Bempegaldesleukin Plus Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT03435640

Study #:
STUDY00143248

Start Date:
Jun 09, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03435640

View Complete Trial Details & Eligibility at ClinicalTrials.gov